Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Clinical Trials
1.9k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1451 trials with phase data)• Click on a phase to view related trials
Study of How People Make Decisions About Prostate Cancer Risk
- Conditions
- High Risk Prostate Cancer
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT07197723
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- Conditions
- ObesityChild ObesityWeight Loss
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1314
- Registration Number
- NCT07144800
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
- Conditions
- Primary Central Nervous System (CNS) LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- Biological: MB-CART19.1 Cellular Therapy
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT07137494
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer in People With Oral Tongue Cance
- Conditions
- Tongue Cancer
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07124520
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸Memoral Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer
- Conditions
- Solid Tumor Cancer
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07117461
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Medisys Health Network (Data Collection Only), Richmond Hill, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 376
- Next
News
Conflicting Results Emerge from Two Major Trials Comparing Proton Beam Therapy to IMRT for Head and Neck Cancer
Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.
Myriad Genetics and SOPHiA GENETICS Partner to Develop Global Liquid Biopsy Companion Diagnostic Platform
Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop an innovative global liquid biopsy companion diagnostic test for pharmaceutical companies.
GeneDx Strengthens Leadership Team with Key Appointments to Advance AI-Powered Precision Medicine
GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.
FORE Biotherapeutics Reports Durable Clinical Benefit with Plixorafenib in BRAF-Altered Thyroid Cancers
FORE Biotherapeutics presented Phase 1/2a data showing plixorafenib achieved a median progression-free survival of 64 months and 85.7% clinical benefit rate in MAPK inhibitor-naïve BRAF V600-mutated papillary thyroid cancer patients.
CheckMate 77T Trial Shows Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC
Perioperative nivolumab demonstrated no negative impact on health-related quality of life while reducing the risk of deterioration compared to placebo in patients with stage III N2 or non-N2 non-small cell lung cancer.
BostonGene's AI Model Identifies Five Novel Subtypes to Predict Immunotherapy Response in Kidney Cancer
BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples.
Abdera Therapeutics Reports Promising Early Data for DLL3-Targeted Radiopharmaceutical ABD-147 in Small Cell Lung Cancer
Abdera Therapeutics presented initial Phase 1 clinical data for ABD-147, a novel DLL3-targeting radiopharmaceutical delivering Actinium-225 to small cell lung cancer tumors.
MASCC Fellow Advocates for Comprehensive Supportive Oncology Integration in Cancer Centers
Dr. Declan Walsh, newly named 2025 MASCC Fellow, emphasizes the critical need for formal supportive oncology departments within cancer centers to coordinate existing services more effectively.
Tempus AI Acquires Paige to Build World's Largest Oncology Foundation Model
Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides.
ARCHER Trial Opens Enrollment to Test Shortened Radiation Therapy for Muscle Invasive Bladder Cancer
The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.